Craft
Immunocore

Immunocore

Patents (US)

6

Oct, 2020

Revenue

£26.5 M

FY, 2021

Market Capitalization

$2 B

2022-09-20

Immunocore Summary

Company summary

Overview
Immunocore is a T cell receptor (TCR) biotechnology company working to create biological therapies for oncology and infectious and autoimmune diseases. It develops ImmTAC (Immune Mobilizing Monoclonal TCRs Against Cancer) molecules, ImmTAV and ImmTAB (Immune Mobilizing Monoclonal TCRs Against Virus or Bacteria) molecules, and ImmTAAI (Immune Mobilizing Monoclonal TCRs Against Autoimmune Disease) molecules. The company uses human TCRs to overcome the limitations of a natural immune system and current therapeutic approaches through engineering bispecific.
Type
Public
Founded
2008
HQ
Milton, GB | view all locations
Website
http://immunocore.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Bahija Jallal

    Bahija Jallal, Chief Executive Officer

  • Brian di Donato

    Brian di Donato, Chief Financial Officer and Head of Strategy

  • Frankie Webster

    Frankie Webster, Chief People Officer

  • Annelise Vuidepot

    Annelise Vuidepot, Chief Technology Officer (CTO) & Head of Pipeline and Platform Research

Operating MetricsView all

Patents (US)

6

Oct, 2020

Patents (Foreign)

145

Oct, 2020

Patent Applications (US)

8

Oct, 2020

LocationsView all

3 locations detected

  • Milton, England HQ

    United Kingdom

    92 Park Dr

  • Conshohocken, PA

    United States

    181 Washington St #200

  • Rockville, MD

    United States

    2273 Research Blvd #220

Immunocore Financials

Summary financials

Revenue (FY, 2021)
£26.5M
Gross profit (FY, 2021)
£26.6M
Net income (FY, 2021)
(£131.5M)
Cash (FY, 2021)
£237.9M
EBIT (FY, 2021)
(£135.4M)
Enterprise value
$1.8B

Footer menu